• Business
  • Entertainment
  • Health
  • News
  • Sport
  • Tech
  • World
Newsy Today
news of today
Home - Endocrine
Tag:

Endocrine

Health

Why Cutting Sugar Could Damage Your Gut Health

by Chief Editor June 18, 2026
written by Chief Editor

Eliminating sucrose from a low-fat diet may disrupt gut health and trigger metabolic dysfunction, according to research presented at the Endocrine Society’s annual meeting, ENDO 2026. While high-sugar consumption is linked to health risks, a 16-week study by the Dasman Diabetes Institute indicates that a total absence of dietary sugar can lead to gut bacteria imbalances, intestinal inflammation, and signs of fatty liver disease.

Why Might Removing All Sugar Harm Gut Health?

Researchers at the Dasman Diabetes Institute in Kuwait City found that mice fed a strictly sugar-free, low-fat diet developed unexpected metabolic issues compared to a control group consuming standard levels of sucrose. Despite maintaining similar body weights, the sugar-free group showed significant internal changes. According to Rasheed Ahmad, principal scientist and head of the Immunology & Microbiology Department at the institute, the total removal of sucrose promoted inflammation and disrupted the delicate balance of the gut microbiome.

Why Might Removing All Sugar Harm Gut Health?
Did you know?

The study observed that mice deprived of all sucrose developed signs of insulin resistance and poor glucose regulation, despite not gaining weight during the 16-week trial period.

What Are the Risks of Strict Sugar Elimination?

The study identifies a potential link between the absence of dietary carbohydrates and the development of cellular markers associated with fatty liver disease. Ahmad noted that while the dangers of excessive sugar are well-documented, the impact of complete elimination remains under-researched. The findings suggest that carbohydrates serve a functional role in supporting immune system health and maintaining the diversity of gut bacteria. Experts caution that these outcomes highlight how extreme dietary restrictions can inadvertently trigger metabolic dysfunction.

How Does This Compare to Current Dietary Trends?

Current health advice often emphasizes the reduction of added sugars, but this research suggests a need for more nuanced guidelines. Unlike ketogenic or high-fat diets, which naturally limit certain carbohydrates, this study focused specifically on removing sucrose from low-fat meals. Researchers emphasize that these findings may not apply to every dietary pattern. Future clinical trials are required to determine if humans experience similar physiological responses when completely eliminating sucrose from their diets.

Join the Diabetes & Endocrinology Research Update 2026 – CPD at The Park, Somajiguda on 21st June.

Pro Tips for Balanced Nutrition

  • Focus on Diversity: Rather than total elimination, prioritize a wide variety of fiber-rich plant foods to support gut bacteria.
  • Consult Professionals: Before making drastic changes to your carbohydrate intake, speak with a registered dietitian to ensure metabolic balance.
  • Monitor Internal Health: Pay attention to signs of inflammation rather than focusing solely on weight as a metric of health.

Frequently Asked Questions

Does this mean I should eat more sugar?
No. The study highlights the risks of complete elimination from a low-fat diet, but it does not endorse high-sugar consumption. Researchers suggest a balanced approach to nutrition is key.

Pro Tips for Balanced Nutrition

Are these results applicable to humans?
The research was conducted on mice over 16 weeks. Further clinical trials are necessary to verify if these effects occur in human subjects.

What is the main takeaway for my diet?
According to the Dasman Diabetes Institute, future dietary guidelines may shift away from strict, absolute sugar bans toward maintaining a diverse and healthy gut microbiome through balanced nutrition.


Have you recently adjusted your sugar intake? Share your experience or questions in the comments below, and subscribe to our health newsletter for the latest updates on metabolic research and nutritional science.

June 18, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

GLP-1 Drugs: Study Highlights Frequent Stop-and-Start Patterns

by Chief Editor June 14, 2026
written by Chief Editor

Nearly 4 in 10 patients with type 2 diabetes stop their GLP-1 medication within the first year of treatment, according to research presented at the Endocrine Society’s annual meeting, ENDO 2026. While discontinuation rates climb to nearly 6 in 10 by the end of two years, the data reveals a high frequency of patients restarting their therapy, suggesting a cyclical “start-and-stop” pattern rather than permanent abandonment of treatment.

Why do patients stop GLP-1 medications?

Discontinuation is often driven by demographic factors and side effects, according to Sainikhil Sontha, a research associate at the Boston University School of Public Health. Analysis of claims data from over 60,000 Americans indicates that patients on Medicaid or Medicare and Black patients face higher risks of dropping their regimen within the first 12 months. Physical barriers also play a significant role: 37% of patients who discontinued treatment reported experiencing nausea or other gastrointestinal side effects.

Pro Tip: Patients prescribed GLP-1 medications by an endocrinologist were 10% less likely to stop their treatment compared to those managed by other providers, suggesting that specialized oversight may improve long-term adherence.

Does the choice of drug influence long-term adherence?

The specific medication prescribed appears to influence how long a patient remains on therapy. Research presented by Sontha shows that patients taking newer medications, such as tirzepatide, were 41% less likely to discontinue treatment than those taking older drugs like liraglutide. Similarly, semaglutide users were 28% less likely to stop their medication compared to those on older, traditional therapies. This trend suggests that newer formulations may offer better tolerability or efficacy, which helps patients maintain their treatment schedules.

Does the choice of drug influence long-term adherence?

What is the impact of a “start-and-stop” pattern?

The cyclical nature of GLP-1 use carries clinical risks. Sontha notes that consistent use is essential for the medication’s protective effects, which include reducing the risk of heart attacks and preventing the progression of kidney disease. Interrupted treatment can lead to missed opportunities for these long-term health benefits. However, the data offers a silver lining: among those who stop, 41.5% restart within a year, and 58% return to therapy within two years, indicating that many patients eventually return to their treatment plans.

What is the impact of a "start-and-stop" pattern?
Did you know? While many assume that stopping a medication means a patient has given up, the study found that nearly two-thirds of patients who quit their GLP-1 therapy eventually resumed it within two years.

Frequently Asked Questions

  • What is defined as discontinuation in this study? Researchers defined discontinuation as having a gap of more than 60 days in filling a GLP-1 prescription.
  • Are stomach side effects common? Yes, 37% of those who stopped their medication cited nausea or other stomach-related issues as a factor.
  • Does the type of doctor matter? According to the study, patients seen by an endocrinologist were 10% more likely to stay on their medication than those seeing other types of providers.
  • Is this trend specific to obesity? The study focused specifically on adults aged 18 to 64 with a BMI of 25 or higher and a diagnosis of type 2 diabetes.

Are you or a loved one managing type 2 diabetes with GLP-1 medications? Share your experiences in the comments below or subscribe to our newsletter for the latest updates on endocrine health and chronic disease management.

June 14, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

Common Plasticizer Linked to Lifelong Anxiety Risks

by Chief Editor June 14, 2026
written by Chief Editor

Early-life exposure to the common plasticizer di-(2-ethylhexyl) phthalate (DEHP) is linked to increased anxiety-like behavior in adulthood, according to research presented at the Endocrine Society’s annual meeting, ENDO 2026. Scientists from the University of Buenos Aires School of Medicine found that prenatal and postnatal exposure to the chemical in rats caused lasting behavioral changes, including heightened anxiety and increased freezing time, which researchers were able to reverse using GABA agonists and testosterone.

How does DEHP exposure affect neurological development?

DEHP acts as an endocrine-disrupting chemical that interferes with the reproductive and nervous systems during critical growth stages. According to Dr. Osvaldo Juan Ponzo, a professor of physiology at the University of Buenos Aires School of Medicine, the plasticizer influences behavioral patterns long after the initial exposure has ended. In the study, researchers administered DEHP to pregnant rats throughout gestation and the weaning period. Once the male offspring reached 70 days of age, they were tested in an elevated plus maze (EPM), a standard tool for measuring rodent anxiety based on their natural aversion to open, high spaces.

How does DEHP exposure affect neurological development?
Did you know?
DEHP is commonly used to increase the flexibility of consumer goods, including medical devices, toys, shower curtains, and raincoats. Because it is not chemically bound to the plastic, it can leach into the environment over time.

Can the effects of early chemical exposure be reversed?

Neuroendocrine changes caused by DEHP are potentially reversible through targeted treatment, according to the study’s findings. Researchers observed that the rats exposed to DEHP spent less time in the open arms of the maze and exhibited more freezing behavior, indicating higher anxiety. However, when these same animals were treated with GABA agonists—molecules that activate the inhibitory neurotransmitter gamma-aminobutyric acid—or testosterone 14 days prior to testing, their anxiety-like behaviors decreased significantly. This suggests that the chemical’s impact on the brain’s neuroendocrine system may be mediated by these specific pathways.

Can the effects of early chemical exposure be reversed?

What are the long-term implications for human health?

While the study was conducted on rodents, the findings provide a framework for understanding how human endocrine disruptors may shape behavioral health across a lifespan. Regulatory bodies and health organizations continue to monitor phthalates due to their widespread presence in household items. A primary concern for future research is identifying the threshold for safe exposure levels, particularly for pregnant individuals. The University of Buenos Aires team noted that even in the absence of continued DEHP exposure during adulthood, the initial developmental changes persisted, suggesting that the timing of exposure is as critical as the dose.

Dr. Osvaldo Ponzo. XXIV Congreso de Endocrinología y Metabolismo. SAEM 2025

Pro Tip: Reducing Household Exposure

To minimize contact with phthalates like DEHP, experts often recommend choosing glass, stainless steel, or ceramic containers for food storage and heating, as plasticizers can leach into food more easily when heated or exposed to acidic contents.

Pro Tip: Reducing Household Exposure

Frequently Asked Questions

  • What is DEHP?
    DEHP is a type of phthalate, a chemical used to make plastics more flexible and durable. It is found in many industrial and consumer products.
  • How does DEHP influence anxiety?
    According to the University of Buenos Aires research, early-life exposure alters the neuroendocrine system, leading to increased anxiety-like behavior in adulthood.
  • Are these effects permanent?
    The study suggests that while the behavioral changes are long-lasting, they may be reversible in a laboratory setting through the administration of GABA agonists or testosterone.
  • Where can I find more information on endocrine disruptors?
    The Endocrine Society provides updated research and resources regarding the impact of endocrine-disrupting chemicals on human health.

Have you considered how plastic exposure might be impacting your daily environment? Share your thoughts in the comments below or subscribe to our health science newsletter for the latest updates on chemical safety research.

June 14, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

Diabetes Increases Mortality Risk Following Solid-Organ Transplantation

by Chief Editor June 14, 2026
written by Chief Editor

Solid-organ transplant recipients face a significantly higher risk of mortality if they develop diabetes, according to a comprehensive analysis presented at ENDO 2026, the Endocrine Society’s annual meeting. Researchers analyzed data from over 800,000 U.S. patients who underwent transplants between 2003 and 2021, finding that both pre-existing and post-surgery diabetes consistently reduced long-term survival rates across major organ categories.

How Diabetes Affects Long-Term Transplant Survival

The impact of diabetes on survival varies significantly depending on the specific organ transplanted, according to the study led by Mishal Ali of the University of Chicago. Researchers found that the association between a diabetes diagnosis and organ failure risk fluctuates nearly 7-fold based on the organ involved.

How Diabetes Affects Long-Term Transplant Survival

For kidney recipients, the long-term outlook is particularly stark. While the mortality gap between diabetic and non-diabetic patients is relatively small at the one-year mark—roughly one to two additional deaths per 100 patients—it widens dramatically over time. By the 10-year post-transplant mark, nearly 24 out of every 100 kidney recipients with diabetes had died, according to the findings.

Did you know?

The risk of mortality for those who develop new-onset diabetes after surgery is nearly as high as for those who entered the transplant process with a long-standing diagnosis, particularly for heart and liver recipients.

Why Organ-Specific Management is Necessary

Transplant providers must shift toward personalized monitoring strategies because diabetes affects recipients differently based on their organ type, says Alan L. Hutchison, M.D., Ph.D., a transplant hepatologist at UChicago Medicine. While kidney recipients show the highest mortality risk associated with diabetes, lung recipients experienced the smallest increase in risk in the study.

The data suggests that a “one-size-fits-all” approach to post-transplant glucose management is likely insufficient. Clinicians are encouraged to tailor prevention and management plans based on the specific organ transplanted. Patients are advised to engage their medical teams early, asking specific questions about diabetes risk both before the surgery and during the critical months of recovery.

Future Trends in Post-Transplant Care

As the population of transplant recipients grows, the medical community is moving toward more aggressive screening for new-onset diabetes. Because the study confirms that post-surgical diabetes carries a similar danger to pre-existing conditions in heart and liver patients, future care models will likely integrate continuous glucose monitoring (CGM) more frequently in the immediate post-operative window.

Clinical Science at ENDO 2026 | Raghu Mirmira, MD, PhD,

The shift toward precision medicine aims to identify metabolic changes before they result in clinical failure. By quantifying the magnitude of diabetes’ impact, this research provides a benchmark for clinicians to assess how much extra support, such as frequent check-ups or early pharmacological intervention, is required for individual patient profiles.

Pro Tips for Transplant Recipients

  • Ask early: Discuss your individual metabolic risk factors with your surgical team before the procedure.
  • Monitor the transition: Be prepared for increased screening in the months immediately following your transplant, as new-onset diabetes can emerge during this recovery phase.
  • Advocate for a plan: If you are a kidney recipient, specifically request a long-term metabolic health plan, given the higher 10-year mortality data identified in recent studies.

Frequently Asked Questions

Does developing diabetes after a transplant impact survival as much as having it before?
Yes. According to the study, for those receiving a new heart or liver, developing diabetes after the surgery is roughly as dangerous as having had the condition for years.

Which organ transplant recipients are at the highest risk if they have diabetes?
Kidney recipients face the highest risk by a significant margin compared to those who received a lung, heart, or liver transplant, according to the analysis.

Should I be worried about diabetes immediately after my transplant?
The mortality gap is smaller in the first year, but it widens significantly over time. Providers recommend close monitoring for both current and new-onset diabetes to manage these long-term risks effectively.


Have you or a loved one navigated the complexities of post-transplant metabolic health? Share your experiences in the comments below or subscribe to our newsletter for the latest updates on endocrine health and transplant research.

June 14, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

New Guidelines: Personalized Care for Precocious Puberty

by Chief Editor June 14, 2026
written by Chief Editor

New Clinical Guidelines Aim to Reduce Unnecessary Testing for Precocious Puberty

The Endocrine Society has released updated clinical practice guidelines for managing central precocious puberty, emphasizing that not all children showing early signs of development require medical intervention. According to the guidelines, published in The Journal of Clinical Endocrinology & Metabolism, clinicians should prioritize observation for specific subgroups, such as older girls experiencing slowly progressing puberty, to avoid invasive testing and unnecessary treatment.

New Clinical Guidelines Aim to Reduce Unnecessary Testing for Precocious Puberty
Did you know? Central precocious puberty is defined by the brain activating puberty-related hormones before age 8 in girls and before age 9 in boys.

What Defines Central Precocious Puberty?

Central precocious puberty occurs when the brain triggers hormonal signaling prematurely. Dr. Ana Claudia Latronico, chair of the writing group at the University of São Paulo, states that early identification is critical for children who truly need care, but the new framework aims to prevent over-medicalization. Physical markers include breast development in girls, testicular enlargement in boys, and rapid growth spurts. If left unmanaged in significant cases, the condition can lead to psychosocial stress and potential long-term health risks, including heart disease and certain cancers, as noted in the Society’s report.

When Is Treatment Necessary?

Puberty-pausing medication remains the standard intervention for children whose development threatens their adult height or causes significant emotional distress. However, Dr. Stephanie Roberts of Boston Children’s Hospital notes that these medications are not a one-size-fits-all solution. According to the guidelines, many older girls with a slow progression of puberty reach a normal adult height without any medical intervention. Clinicians are now encouraged to use observation periods and simpler diagnostic methods as a first line of defense rather than jumping immediately to advanced testing.

When Is Treatment Necessary?
Pro Tip: If your child displays early signs of puberty, discuss the rate of progression with your pediatrician. The Endocrine Society suggests that “slow-moving” puberty may not require the same clinical urgency as rapidly progressing cases.

Future Trends in Pediatric Endocrinology

The shift toward personalized medicine in pediatric endocrinology reflects a broader trend in healthcare: minimizing invasive procedures. While previous protocols often favored aggressive diagnostic testing, the 2026 guidelines suggest a more nuanced, observational approach. By focusing on individual patient outcomes rather than universal thresholds, the Endocrine Society aims to reduce the physical and financial burden on families. Ongoing research, such as the work led by committee members from institutions like the Mayo Clinic and the University of Copenhagen, continues to refine these diagnostic criteria to distinguish between benign early development and clinically significant precocious puberty.

Future Trends in Pediatric Endocrinology

Frequently Asked Questions

  • At what age is puberty considered “precocious”?
    According to the Endocrine Society, it is defined as puberty starting before age 8 in girls and age 9 in boys.
  • Are there long-term risks to early puberty?
    Yes, untreated cases can be associated with psychosocial stress, heart disease, and some cancers in adulthood, though not all early development requires treatment.
  • What is the primary treatment for precocious puberty?
    Clinicians typically use puberty-pausing medication to temporarily stop brain signals that initiate physical development, allowing for improved height and emotional outcomes.
  • Do all children with early puberty need treatment?
    No. The latest guidelines emphasize that some subgroups, particularly older girls with slow-progressing puberty, may not need treatment and can instead be monitored by their health care provider.

For more information on child development and pediatric health, subscribe to our newsletter or browse our archives on pediatric endocrinology. Have a question about these new guidelines? Share your thoughts in the comments section below.

June 14, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

Mapping Genetic Drivers of Prostate Cancer Treatment Resistance

by Chief Editor May 22, 2026
written by Chief Editor

The Future of Prostate Cancer Treatment: Breaking the Cycle of Therapy Resistance

Prostate cancer remains a formidable challenge in global health, with its complexity evolving alongside the very treatments designed to combat it. A recent review published in the journal Research (DOI: 10.34133/research.1128) sheds new light on the mechanisms driving therapy resistance, providing a roadmap for the next generation of precision medicine.

The Future of Prostate Cancer Treatment: Breaking the Cycle of Therapy Resistance
Feng

Led by Dr. Dechao Feng of University College London and Zhejiang Provincial People’s Hospital, the research highlights a critical shift: moving from one-size-fits-all endocrine therapy to highly individualized management strategies that account for the tumor’s adaptive nature.

Understanding the “Escape” Mechanisms

Standard care often involves Androgen Deprivation Therapy (ADT) and Androgen Receptor Signaling Inhibitors (ARSIs). While these are effective initially, the cancer frequently finds ways to bypass these barriers. Dr. Feng’s team identifies that prostate cancer cells are not static; they undergo metabolic reprogramming to maintain androgen levels even when systemic supplies are cut off.

Did you know?

Prostate cancer cells can utilize adrenal-derived precursors and even de novo synthesis to produce testosterone and dihydrotestosterone, effectively “feeding” the tumor despite systemic treatment.

The Challenge of Lineage Plasticity

One of the most concerning trends in advanced prostate cancer is the evolution toward aggressive, “double-negative” (DNPC) or neuroendocrine (NEPC) subtypes. These variants lack the traditional androgen receptor (AR) expression, rendering standard hormonal therapies ineffective.

Post-ESMO 2025 Highlights: Advances in Prostate Cancer Research with Andrew W. Hahn, MD
  • Spatiotemporal Heterogeneity: Different metastatic sites within the same patient may harbor entirely different molecular profiles.
  • Genetic Drivers: Losses in genes such as TP53, RB1, and KMT2C are key contributors to this aggressive lineage transformation.

Precision Medicine: The Next Frontier

To overcome these resistance barriers, the future of oncology must move beyond static snapshots of the disease. The research emphasizes a transition toward “whole-course” management, integrating several advanced technologies:

  1. Single-cell and Spatial Multi-omics: Capturing the high-resolution landscape of tumor evolution in real-time.
  2. Liquid Biopsies: Enabling continuous monitoring of disease progression without invasive repeat biopsies.
  3. Organoid Models: Providing a platform to test patient-specific drug sensitivities before clinical application.
Pro Tip:

Clinicians should look toward biomarker-stratified clinical trials. By identifying the specific bypass signaling pathways—such as PI3K/AKT or WNT/β-catenin—physicians can better tailor combinatorial therapies to block the tumor’s escape routes.

Frequently Asked Questions (FAQ)

What is the primary cause of resistance to prostate cancer therapy?
Resistance is primarily driven by the adaptive remodeling of the androgen receptor pathway and metabolic reprogramming that allows the tumor to synthesize its own androgens despite endocrine therapy.

Why do some prostate cancers become more aggressive over time?
Under the pressure of therapy, tumors can undergo “lineage plasticity,” where they lose their luminal identity and evolve into more aggressive, AR-independent subtypes like DNPC or NEPC.

How will future treatments differ from current ones?
Future strategies will focus on dynamic monitoring using multi-omics and organoid models, allowing for personalized, combinatorial approaches that target both the AR pathway and the alternative signaling routes the cancer uses to survive.


Are you interested in the latest breakthroughs in oncology and precision medicine? Subscribe to our newsletter for deep dives into peer-reviewed research or leave a comment below to share your thoughts on the future of cancer care.

May 22, 2026 0 comments
0 FacebookTwitterPinterestEmail

Recent Posts

  • Charming €180k Irish Townhouse With Original Features and Private Patio

    June 21, 2026
  • Is Modern Pop Music Getting Worse? An Analysis

    June 21, 2026
  • Apple’s Upcoming Product Lineup for the Rest of the Year

    June 21, 2026
  • Jason Dickinson Re-signs with Oilers: 5-Year, $20M Deal

    June 21, 2026
  • Tragic Sea Incident: Three Teenagers Die in Tarragona

    June 21, 2026

Popular Posts

  • 1

    Maya Jama flaunts her taut midriff in a white crop top and denim jeans during holiday as she shares New York pub crawl story

    April 5, 2025
  • 2

    Saar-Unternehmen hoffen auf tiefgreifende Reformen

    March 26, 2025
  • 3

    Marta Daddato: vita e racconti tra YouTube e podcast

    April 7, 2025
  • 4

    Unlocking Success: Why the FPÖ Could Outperform Projections and Transform Austria’s Political Landscape

    April 26, 2025
  • 5

    Mecimapro Apologizes for DAY6 Concert Chaos: Understanding the Controversy

    May 6, 2025

Follow Me

Follow Me
  • Cookie Policy
  • CORRECTIONS POLICY
  • PRIVACY POLICY
  • TERMS OF SERVICE

Hosted by Byohosting – Most Recommended Web Hosting – for complains, abuse, advertising contact: o f f i c e @byohosting.com


Back To Top
Newsy Today
  • Business
  • Entertainment
  • Health
  • News
  • Sport
  • Tech
  • World